Sagimet Biosciences Reports 2025 Financial Results and MASH/Acne Program Updates

Sagimet Biosciences Inc.

Cash and marketable securities $113.1M; net loss $51M for full year 2025.
Completed Phase 1 PK trial of denifanstat+resmetirom; Phase 2 combo trial in F4 MASH expected 2H 2026.
Exclusive license from TAPI for innovative resmetirom API forms to develop fixed-dose combination.
Ascletis reported positive Phase 3 acne data for denifanstat; NDA accepted by China NMPA.
Initiated Phase 1 trial of TVB-3567, a FASN inhibitor for acne.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sagimet Biosciences Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 11, 2026, Sagimet Biosciences Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.

View on SEC.gov

52 earnings releases filed in the last 30 days. Browse all earnings releases →

Sagimet Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-026146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.